Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Recent results from Omada Health’s Digital Diabetes Prevention Program show reductions in A1C and body weight over a 12-month period. This digital tool may be especially...
More people with diabetes are taking drugs like Jardiance and Farxiga, originally developed to lower glucose in people with type 2 diabetes, because the latest data...
How might exercise affect your blood glucose? The T1-DEXI study hopes to answer this big question with real-world data from over 600 people with type 1 diabetes –...
Highlights from last week’s European Association for the Study of Diabetes’ (EASD) virtual 2020 conference included announcements on the Guardian Sensor 4 Continuous...
Experts discussed the greatest challenges in diabetes in 2020, including the COVID-19 pandemic, and the most critical changes we need to make to address them during...
Latest results presented at the European Society of Cardiology conference show that SGLT-2 inhibitor therapies Jardiance and Farxiga clearly lead to heart and kidney...
In exciting news for digital diabetes prevention programs, a new study showed that highly engaged participants – those who more frequently engaged in food logging,...
A summary of the landmark trials that show that careful blood glucose management can lower the risk of long-term health complications in people with type 1 or type 2...
The microbiome is an exciting area of research for diabetes management. What do we know and what questions do we still have about the microbiome?
What is the link between vision loss and mental health outcomes, and how can eye exams tell us what is going on in the brain and the body?
dQ&A surveyed 2,540 CGM users with type 1 or type 2 diabetes to find out how aware they are of their own time in range: 87% of respondents knew how much time they...
Results from the VERTIS-CV trial show that SGLT-2 inhibitor Steglatro benefits heart and kidney health; hear expert opinions on SGLT-2 and GLP-1 medications
The first study of people with diabetes and COVID-19 reveals troubling statistics and risk factors
In exciting news, Tandem announced expanded clearance for the hybrid closed loop Control-IQ. The system is now available for children ages 6-13
Check out the third day highlights from ADA’s virtual 80th Scientific Sessions – including new insights on off label use in type 1 diabetes, type 2 diabetes remission,...
We bring you the most exciting news from day one, including updates on automated insulin delivery, ways that technology can reduce hypoglycemia, and new physical...
Early trial results found that SGLT-2 inhibitor Farxiga is highly effective for preventing and treating kidney disease in people with or without type 2 diabetes
JDRF's Mission Summit in La Jolla, California highlighted JDRF's efforts into multiple cures, plus more on complications
Trulicity can now be prescribed to reduce the risk of stroke and heart attack in adults with type 2 diabetes and with heart disease or those who at risk for heart disease
A new study shows that physical activity can add years to your life. Is this enough to motivate behavior change?

Pages